Does Immunotherapy for Treatment of Reproductive Failure Enhance Live Births?

American Journal of Reproductive Immunology

Volumn 67, Issue 4, 2012, Pages 296-304

  Coulam, Carolyn B ^a   Acacio, Brian ^b  

^a Reproductive Medicine Institute   (United States)

^b Acacio Fertility Center   (United States)

Author keywords

Immunotherapy; Intralipids; Intravenous immunoglobulin; Reproductive failure

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTRALIPID; PHOSPHOLIPID ANTIBODY;

ANTIBODY DETECTION; ANTICOAGULANT THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DISEASE ASSOCIATION; FEMALE; FEMALE INFERTILITY; FERTILIZATION IN VITRO; HUMAN; IMMUNOTHERAPY; INFERTILITY THERAPY; LIVE BIRTH; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; PREGNANCY OUTCOME; PREGNANCY RATE; PRIORITY JOURNAL; RECURRENT ABORTION; REPRODUCTIVE HISTORY; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ABORTION, HABITUAL; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGENS, CD56; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; INFERTILITY, FEMALE; KILLER CELLS, NATURAL; LIVE BIRTH; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; PREGNANCY RATE;

EID: 84858703920     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/j.1600-0897.2012.01111.x     Document Type: Review

References (59)

1. Roussev RG, Kaider BD, Price DE, Coulam CB: Laboratory evaluation of women experiencing reproductive failure. Am J Reprod Immunol 1996; 35:415-420.
2. Sugrt I, Ulcova-Gallova Z, Bibkova K, Micanova Z, Hejnalova M, Cerna M, Hradecky L, Novotny Z: Recurrent pregnancy los and frequency of eight antiphophslipid andtibodes and genetic thrombophilic factors in Czech women. Am J Reprod Immunol 2008; 59:193-200.
3. Kwak-Kim J, Gilman-Sachs A: Clinical implication of natural killer cells and reproduction. Am J Reprod Immunol 2008; 59:388-400.
4. Roberts CJ, Lowe CR: Where have all the conceptions gone? Lancet 1975; 1:498-499.
5. Practice Committee of the American Society for Reproductive Medicine: Definitions of infertility and recurrent pregnancy loss. Fertil Steril 2008; 90:60S.
6. Coulam CB: Implantation failure and immunotherapy. Hum Reprod 1995; 10:1338-1340.
7. Coulam CB, Goodman C, Roussev RG, Thomason EJ, Beaman KD: Systemic CD56+ cells can predict pregnancy outcome. Am J Reprod Immunol 1995; 33:40-46.
8. Kwak JYH, Beaman KD, Gilman-Sachs A, Ruiz JE, Schewitz D, Beer AE: Up-regulated expression of CD56+, CD56+/16+ and CD19+ cells in peripheral blood lymphocytes in woman with recurrent pregnancy losses. Am J Reprod Immunol 1995; 34:93-99.
9. Coulam CB, Roussev RG: Correlation of NK cell activation and inhibition markers with NK cytoxicity among women experiencing immunologic implantation failure after in vitro fertilization and embryo transfer. J Assist Reprod Genet 2003; 20:58-62.
10. Coulam CB, Stephenson M, Stern JJ, Clark DA: Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Am J Reprod Immunol 1996; 35:352-359.
11. Quenby SM, Farquharson RG: Predicting recurring miscarriage: what is important? Obstet Gynecol 1993; 82:132-138.
12. Birkenfeld A, Mukaida T, Minichiello L, Jackson M, Kase NG, Yemini M: Incidence of autoimmune antibodies in failed embryo transfer cycles. Am J Reprod Immunol 1994; 31:65-68.
13. Dmowski WP, Rana N, Michalowska J, Finberg J, Papierniak C, El-Roeiy A: The effect of endometriotic stage and activity and antibodies on in vitro fertilization and embryo transfer success rates. Fertil Steril 1995; 63:555-562.
14. Geva E, Yaron Y, Lessing JB, Yovel I, Vardion N, Burke M, Amit A: Circulating autoimmune antibodies may be responsible for implantation failure in in vitro fertilization. Fertil Steril 1994; 62:802-806.
15. Sher G, Feinman M, Zouves C, Kuttner G, Maassarani G, Salem R, Matzner W, Ching W, Chong P: High fecundity rates following in vitro fertilization and embryo transfer in antiphospholipid antibody seropositive women treated with heparin and aspirin. Hum Reprod 1994; 9:2278-2283.
16. Birdsall MA, Lockwood GM, Ledger WI, Johnson PM, Chamley LW: Antiphospholipid antibodies in women having in vitro fertilization. Hum Reprod 1996; 11:1185-1189.
17. Gleicher N, Lui H-C, Dudkiewicz A, Rosenwaks Z, Kaberlein G, Pratt D, Karande V: Autoantibody profiles and immunoglobulin levels as predictors of in vitro fertilization success. Am J Obstet Gynecol 1994; 170:1145-1149.
18. Kutteh WH, Yetman DL, Chanties SJ, Crain J: Effect of antiphospholipid antibodies in women undergoing in vitro fertilization: role of heparin and aspirin. Hum Reprod 1997; 12:1171-1175.
19. Denis AL, Guido M, Adler RD, Bergh PA, Brenner C, Scott RT: Antiphospholipid antibodies and pregnancy rates an outcome in in vitro fertilization patients. Fertil Steril 1997; 67:1084-1090.
20. Kowalik A, Vichnin M, Lui H-C, Branch W, Berkley AS: Midfollicular anticardiolipin and antiphosphatidylserine antibody titers do not correlate with in vitro fertilization outcome. Fertil Steril 1997; 68:298-304.
21. Stern CJ, Norris H, Chamley LW, Baker HWG: A randomized, double-blind, placebo-controlled trial of heparin and aspirin for women with IVF-implantation failure and antiphospholipid or antinuclear antibodies. Hum Reprod 2001. Abstracts of the 17th Annual Meeting of the ESHRE, 74 pp.
22. Tartakowsky V, Bermos BL, Sthoeger Z, Shearer GM, Mozes E: Defective maternal-fetal interaction in a murine autoimmune model. Hum Reprod 1996; 11:2408-2411.
23. Azem F, Geva E, Amit A, Lerner-Geva L, Schwartz T, Ben-Yosef D, Yovel I, Lessing JB: High levels of anticardiolipin antibodies in patients with abnormal embryo morphology who attended and in vitro fertilization program. Am J Reprod Immunol 1998; 39:161-163.
24. Rand JH, Wu XX, Andree HAM, Lockwood CJ, Guller S, Scher J, Harpel PC: Pregnancy loss in the antiphospholipid syndrome-a possible thrombogenic mechanism. N Engl J Med 1997; 337:154-160.
25. Quenby S, Mountfield S, Cartwright JE, Whitley GS, Chamley L, Vince G: Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril 2005; 83:691-698.
26. Di Simone N, Raschi E, Testoni C, Castellani R, D'Asta M, Shi T, Krilis SA, Caruso A, Meroni PL: Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis 2005; 64:462-467.
27. Rote NS, Vogt E, De Vere G, Obringer AR, Ng AK: The role of placental trophoblast in pathophysiology of the antiphospholipid antibody syndrome. Am J Reprod Immunol 1998; 39:125-136.
28. Chamley LW, Duncalf AM, Mitchell MDJohnsonPM, Johnson PM: Action of anticardiolipin and antibodies to beta2-glycoprotein-I on trophoblast proliferation a as a mechanism for fetal death. Lancet 1998; 352:1037-1038.
29. Bose P, Black S, Kadyrov M, Betz C, Shlebak A, Regan L, Hubberta B: Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol 2004; 191:2125-2131.
30. Kaider BD, Coulam CB, Roussev RG: Murine embryos as a direct target for some human autoantibodies in vitro. Hum Reprod 1999; 10:2556-2561.
31. Girardi G, Bulla R, Salmon JE, Tedesco F: The complement system in the pathophysiology of pregnancy. Mol Immunol 2006; 43:68-77.
32. Kutteh WH: Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174:1584-1589.
33. Rai R, Cohen H, Dave M, Regan L: Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314:253-257.
34. Kwak JYH, Gilman-Sachs A, Beaman KD, Beer AE: Reproductive outcome in women with recurrent spontaneous abortions of alloimmune and autoimmune causes: preconception versus postconception treatment. Am J Obstet Gynecol 1992; 166:1787-1798.
35. Girling JE, Rogers PA: Recent advances in endometrial angiogenesis research. Angiogenesis 2005; 8:89-99.
36. Smith SK: Angiogenesis and reproduction. BJOG 2001; 108:777-783.
37. Carroll TY, Mulla MJ, Han CS, Brosens JJ, Chamley LW, Giles I, Pericleous C, Rahman A, Sfakianaki AK, Paidas MJ, Abrahams VM: Modulation of trophoblast angiogenic factor secretion by antiphospholipid antibodies is not reversed by heparin. Am J Reprod Immunol 2011; 66:286-296.
38. Clark DA, Coulam CB, Strickler RB: Is intravenous immunoglobulins (IVIG) efficacious in early pregnancy failure? A critical review and meta-analysis for patients who fail in vitro fertilization and embryo transfer (IVF). J Assist Reprod Genet 2006; 23:1-13.
39. Coulam CB, Stephenson M, Stern JJ, Clark DA: Immunotherapy for recurrent pregnancy loss: analysis of results from clinical trials. Am J Reprod Immunol 1996; 35:330-337.
40. Coulam CB, Roussev RG: Chemical pregnancies: immunologic and ultrsonographic studies. Am J Reprod Immunol 2002; 48:323-328.
41. Aoki K, Kajijura S, Matsumoto Y, Okada S, Yagami Y, Gleicher N: Preconceptional natural killer cell activity as a predictor of miscarriage. Lancet 1995; 135:1340-1342.
42. Yamada H, Morikawa M, Kato EH, Shimada S, Kobashi G, Minakami H: Preconceptional natural killer cell activity and percentage as predictors of biochemical pregnancy and spontaneous abortion with a normal karyotype. Am J Reprod Immunol 2003; 50:351-354.
43. Roumen GR, Ng SC, Coulam CB: Natural killer cell functional activity suppression by intravenous immunoglobulin, intralipid and soluble human leukocyte antigen-G. Am J Reprod Immunol 2007; 57:262-269.
44. Ruiz JE, Kwak JY, Baum L, Gilman-Sachs A, Beaman KD, Kim YB, Beer AE: Effects of intravenous immunoglobulin G on natural killer cell cytotoxicity in vitro in women with recurrent spontaneous abortion. J Reprod Immunol 1996; 31:125-141.
45. Kwak JY, Kwak FM, Ainbinder SW, Ruiz AM, Beer AE: Elevated peripheral blood natural killer cells are effectively downregulated by immunoglobulin G infusion in women with recurrent spontaneous abortions. Am J Reprod Immunol 1996; 35:363-369.
46. Sewell WAC, Jolles S: Immunomodulatory action of intravenous immunoglobulins. Immunology 2002; 107:387-393.
47. Granato D, Blum S, Rossle C, Le Boucher J, Malnos A, Dutot G: Effects of parenteral lipid emulsions with different fatty acid composition on immune cell functions in vitro. JPEN J Parenter Enteral Nutr 2000; 24:113-118.
48. Mayer K, Meyer S, Reinholz-Muhly M, Maus U, Merfels M, Lohmeyer J, Grimminger F, Seeger W: Short-time infusion of fish-oil based lipid emulsions, approved for parenteral nutrition, reduces monocyte proinflammatory cytokine generation and adhesive interaction with endothelium in humans. J Immunol 2003; 171:4837-4843.
49. Krog J, Hoklland M, Ahlburg P, Parner E, Tonnesen E: Lipid solubility and concentration dependent attenuation of in vitro natural killer cell cytotoxicity by local anesthetics. Acta Anaesthesiol Scand 2002; 46:875-881.
50. Inoue H, Miyaji M, Kosugi A, Nagafukku M, Okazaki T, Mimori T, Amakawa R, Fukuhara S, Domae N, Bloom ET, Umehara H: Lipid rafts as the signaling scaffold for NK cell activation: tyrosine phosphorylation and association of LAT with phosphotidlyinositol 3-kinase and phospholipase C-gamma following CD2 stimulation. Eur J Immunol 2002; 32:2188-2198.
51. Roumen GR, Acacio B, Ng SC, Coulam CB: Duration of intralipid's suppressive effect on NK Ccell's functional activity. Am J Reprod Immunol 2008; 60:258-263.
52. Khan SA, Vanden-Heuvel JP: Role of nuclear receptors in the regulation of gene expression by dietary fatty acids (review). J Nutr Biochem 2003; 14:554-567.
53. Kostenis E: A glance a G-protein-coupled receptors for lipid mediators: a growing receptor family with remarkable diverse ligands. Pharmacol Ther 2004; 102:243-257.
54. Leslie D, Dascher CC, Cembrola K, Townes MA, Have DL, Hugendubler LC, Mueller E, Fox L, Roura-Mir C, Moody DB, Vincent MS, Gumperz JE, Illarionov PA, Besra GS, Reynolds CG, Brenner MB: Serum lipids regulate dendritic cell CD1 expression and function. Immunology 2008; 125:289-301.
55. Clark DA: Intralipid as a treatment for recurrent unexplained abortion? Am J Reprod Immunol 1994; 32:290-293.
56. Sedman PC, Somers SS, Ramsden CW, Brennan TG, Guillou PJ: Effects of different lipid emulsions on lymphocyte function during total parenteral nutrition. Br J Surg 1991; 78:1396-1399.
57. Tezuka H, Sawada H, Sakoda H, Itoh K, Nishikori M, Amagai T, Uchino H, Mori KJ: Suppression of genetic resistance to bone marrow grafts and natural killer activity by administration of fat emulsion. Exp Hematol 1988; 12:609-612.
58. Clark DA: The power of observation. Am J Reprod Immunol 2011; 66:71-75.
59. Schenk LM, Butler L, Morris JP: Heparin and aspirin treatment yields higher implantation rates in IVF patients with antiphospholipid seropositivity compared to untreated seronegative patients. American Society of Reproductive Medicine, November 1996, Boston MA, USA, Abstract O-076.